A drugmaker-funded study in The Lancet Neurology showed a newer antipsychotic, pimavanserin, may reduce psychosis symptoms in Alzheimer's disease patients without the side effects linked to other antipsychotics. Pimavanserin blocks the THT2A nerve receptor in the brain.
Study looks at newer antipsychotic among Alzheimer's patients
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.